Phase III, Multi-Center, Open-Label, Randomized Study Of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia In Chronic Phase

Grants and Contracts Details

StatusActive
Effective start/end date8/17/2110/30/24

Funding

  • Novartis (domestic): $160,175.00